CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis

Fais, Franco; Tenca, Claudya; Cimino, Giuseppe; Coletti, Valentina; Zanardi, Silvia; Bagnara, Davide; Saverino, Danièle; Zarcone, Daniela; Rossi, Giulio De; Ciccone, Ermanno; Grossi, Carlo E.

doi:10.1038/sj.leu.2403671

Cited by 50 publications

(41 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is to be noted that inhibition of cytotoxicity is never complete using α-CD1d moAb in blocking experiments. 4,22 C1R-CD1d cell lysis occurred irrespective of the NKT cell sub-type (NKTD and NKT-Fe). 7 NKT cells and α-GalCer was able to reduce the tumor mass while two consecutive doses of 1×10 7 NKT and α-GalCer completely eradicated the nodule.…”

Section: Discussionmentioning

confidence: 99%

“…These cells have been shown to be capable of killing CD1d + tumoral cells in several studies. [3][4][5][6] We therefore evaluated whether NKT cells were suitable for use in vivo against CD1d + leukemic cells by setting up an experimental model using CD1d…”

Section: Discussionmentioning

confidence: 99%

“…The phenotype and the functional features were reported previously. 3,4 NKTD and NKT-Fe cell lines were composed mostly of CD4 + T cells.…”

Section: Isolation Of Nkta Cell Linementioning

confidence: 99%

“…[3][4][5][6] We previously showed that the CD1d molecule is expressed on B-cell chronic lymphocytic leukemia (B-CLL) cells 3 and in a severe prognosis sub-group of childhood B-cell acute lymphoblastic leukemia (BCP-ALL) carrying the 11q23 rearrangement. 4 In addition, expression of CD1d has been demonstrated on myeloma 2,17 and myelo-monocytic leukemia cells. 5 CD1d + leukemic cells were found to be capable of α-GalCer presentation and susceptible to NKT cell mediated lysis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms

Bagnara¹,

Ibatici²,

Corselli³

et al. 2009

Haematologica

View full text Add to dashboard Cite

The online version of this article contains a supplementary appendix. BackgroundCD1d is a monomorphic antigen presentation molecule expressed in several hematologic malignancies. Alpha-galactosylceramide (α-GalCer) is a glycolipid that can be presented to cytotoxic CD1d-restricted T cells. These reagents represent a potentially powerful tool for cell mediated immunotherapy. Design and MethodsWe set up an experimental model to evaluate the use of adoptively transferred cytotoxic CD1d-restricted T cells and α-GalCer in the treatment of mice engrafted with CD1d + lymphoid neoplastic cells. To this end the C1R cell line was transfected with CD1c or CD1d molecules. In addition, upon retroviral infection firefly luciferase was expressed on C1R transfected cell lines allowing the evaluation of tumor growth in xenografted immunodeficient NOD/SCID mice. ResultsThe C1R-CD1d cell line was highly susceptible to specific CD1d-restricted T cell cytotoxicity in the presence α-GalCer in vitro. After adoptive transfer of CD1d-restricted T cells and α-GalCer to mice engrafted with both C1R-CD1c and C1R-CD1d, a reduction in tumor growth was observed only in CD1d + masses. In addition, CD1d-restricted T-cell treatment plus α-GalCer eradicated small C1R-CD1d + nodules. Immunohistochemical analysis revealed that infiltrating NKT cells were mainly observed in CD1d nodules. ConclusionsOur results indicate that ex vivo expanded cytotoxic CD1d-restricted T cells and α-GalCer may represent a new immunotherapeutic tool for treatment of CD1d + hematologic malignancies.Key words: lymphoproliferative disorders, natural killer T cells, α-galactosylceramide, CD1d, CD1d-restricted T cells. Ibatici A, Corselli M, Sessarego N, Tenca C, De Santanna A, Mazzarello A, Daga A, Corvò R, De Rossi G, Frassoni F, Ciccone E, and Fais F CD1d-expressing lymphoid neoplasms. Haematologica 2009;94:967-974.doi:10.3324/haematol.2008 This is an open-access paper. Citation: Bagnara D, . Adoptive immunotherapy mediated by ex vivo expanded natual killer T cells against Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…The phenotype and the functional features were reported previously. 3,4 NKTD and NKT-Fe cell lines were composed mostly of CD4 + T cells.…”

Section: Isolation Of Nkta Cell Linementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms

Bagnara¹,

Ibatici²,

Corselli³

et al. 2009

Haematologica

View full text Add to dashboard Cite

show abstract

“…Aberrant expression of b-catenin, which plays a central role in Wnt signaling, is associated with a poor prognosis in patients with acute myeloid leukemia (38,39). Interestingly, a recent study showed that a subgroup of patients with acute lymphoblastic leukemia was associated with a poor prognosis when the leukemia cells express CD1d (40). Our data showing that LEF-1 can regulate the CD1D gene would help to establish a relationship between Wnt signaling and CD1D gene regulation, which may reveal the mechanism behind these clinical observations.…”

Section: Discussionmentioning

confidence: 99%

Human CD1D Gene Expression Is Regulated by LEF-1 through Distal Promoter Regulatory Elements

Chen¹,

Zhang

Pincus

et al. 2010

The Journal of Immunology

View full text Add to dashboard Cite

CD1d-expressing cells present lipid Ag to CD1d-restricted NKT cells, which play an important role in immune regulation and tumor rejection. Lymphoid enhancer-binding factor-1 (LEF-1) is one of the regulators of the Wnt signaling pathway, which is a powerful regulator in cellular growth, differentiation, and transformation. There is little evidence connecting Wnt signaling to CD1d expression. In this study, we have identified LEF-1 as a regulator of the expression of the gene encoding the human CD1d molecule (CD1D). We found that LEF-1 binds specifically to the CD1D promoter. Overexpression of LEF-1 in K562 or Jurkat cells suppresses CD1D promoter activity and downregulates endogenous CD1D transcripts, whereas knockdown of LEF-1 using LEF-1-specific small interfering RNA increases CD1D transcripts in K562 and Jurkat cells but there are different levels of surface CD1d on these two cell types. Chromatin immunoprecipitation showed that the endogenous LEF-1 is situated at the CD1D promoter and interacts with histone deacetylase-1 to facilitate the transcriptional repressor activity. Knockdown of LEF-1 using small interfering RNA potentiates an acetylation state of histone H3/H4, supporting the notion that LEF-1 acts as a transcriptional repressor for the CD1D gene. Our finding links LEF-1 to CD1D and suggests a role of Wnt signaling in the regulation of the human CD1D gene.

show abstract

Acute Lymphoblastic Leukaemia and Acute Leukaemia of Ambiguous Lineage

2017

Leukaemia Diagnosis

View full text Add to dashboard Cite

CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis

Cited by 50 publications

References 16 publications

Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms

Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms

Human CD1D Gene Expression Is Regulated by LEF-1 through Distal Promoter Regulatory Elements

Acute Lymphoblastic Leukaemia and Acute Leukaemia of Ambiguous Lineage

Contact Info

Product

Resources

About